• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Adnavance Technologies

edit

Adnavance Technologies is an early-stage developer of direct detection molecular diagnostic tests. The company’s patented and ultra-sensitive metalized-DNA (M-DNA™) technology may eliminate the need for amplification for a large number of these tests. This technology provides many significant advantages over existing methods, including ease of use, time to result and cost. The platform is simple and inexpensive and is expected to receive FDA approval for use by any laboratory.

Milestones

edit

• 
  Adnavance Technologies received $3.85M in Series A funding. (11/29/05)
  Posted 8/31/10 at 3:26am via biospace.com
• 
  Adnavance Technologies received $3.74M (C$3.7M) in Series B funding. (2/26/08)
  Posted 12/18/09 at 1:10am via adnavance.com

Videos

Screenshots

edit

Above: Adnavance Technologies
Uploaded: 12/18/09

Sources

1. Adnavance Technologies Inc. Secures Series A Financing Totaling $3.85 M (biospace.com) [edit]
2. Adnavance Technologies Completes $3.7 Million Financing (adnavance.com) [edit]